Short answer · Medically reviewed summary · Last updated: 2026-04-07
Factor V Leiden was first identified in 1994 by a team of Dutch researchers who discovered that a specific genetic mutation caused resistance to activated protein C, a key mechanism in blood clotting. The Discovery of a Genetic Clotting Risk Before the mid-1990s, clinicians observed that many patients suffering from unexplained venous thromboembolism (VTE) did not have a clear cause for their hypercoagulability. In 1994, Dr.
3 people with Factor V Leiden have shared their first-person experience on this question at DiseaseMaps.
What is the history of Factor V Leiden?
History of Factor V Leiden: when and how it was discovered, and the milestones in research since, medically reviewed.
Factor V Leiden was first identified in 1994 by a team of Dutch researchers who discovered that a specific genetic mutation caused resistance to activated protein C, a key mechanism in blood clotting.
The Discovery of a Genetic Clotting Risk
Before the mid-1990s, clinicians observed that many patients suffering from unexplained venous thromboembolism (VTE) did not have a clear cause for their hypercoagulability. In 1994, Dr. Rogier Bertina and his colleagues at Leiden University Medical Center in the Netherlands pinpointed the cause: a point mutation in the F5 gene. This discovery of Factor V Leiden fundamentally changed hematology by identifying the most common hereditary thrombophilia in populations of European descent.
Evolution of Understanding and Treatment
Historically, the medical community struggled to explain why some individuals experienced recurrent clots while others with the same mutation remained asymptomatic. As our understanding of Factor V Leiden evolved, researchers realized that the risk is often "multi-factorial." We now know that Factor V Leiden rarely acts alone; it frequently interacts with environmental factors like pregnancy, hormone replacement therapy, or prolonged immobility to trigger a clot. Treatment has moved from broad, long-term anticoagulation for all carriers to a personalized approach, focusing on risk stratification and prophylactic measures like compression stockings or temporary anticoagulation during high-risk scenarios.
Shifting Paradigms
Early misconceptions often led to unnecessary alarm, with patients fearing that a positive test for Factor V Leiden guaranteed a life-threatening event. Modern genetics have clarified that being a heterozygote (inheriting one copy) carries a relatively low absolute risk of thrombosis compared to homozygotes (inheriting two copies). Today, patient advocacy groups and platforms like DiseaseMaps.org empower individuals with Factor V Leiden to focus on education and symptom awareness rather than constant fear, shifting the clinical focus toward preventing complications through lifestyle management and informed medical decision-making.
Medical Disclaimer: This information is for educational purposes and should not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- Online Mendelian Inheritance in Man (OMIM)
- Orphanet: The portal for rare diseases and orphan drugs
Factor V was discovered in 1994 in Leiden Netherlands.
Posted Sep 1, 2017 by Stacy 2650
Factor five is produced by the liver and circulates in the blood, generally inactive until there is a injury to a vessel wall, than specific proteins will be activated in response to the injury.
Not everyone who gets blood clots will have FVL. There are many reason for any person to be at risk for clots, such as, fractures, hormone replacement therapy, surgery, birth control. Those with FVL can just have a greater risk.
Posted Dec 28, 2017 by Barbara 4050
Posted Feb 28, 2019 by [email protected] 100
